Abera Bioscience AB (FRA:8WK)

Abera Bioscience AB Statistics

Total Valuation

FRA:8WK has a market cap or net worth of EUR 12.29 million. The enterprise value is 10.09 million.

Market Cap	12.29M
Enterprise Value	10.09M

Important Dates

The last earnings date was Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	20.50M
Shares Outstanding	n/a
Shares Change (YoY)	+17.39%
Shares Change (QoQ)	+10.46%
Owned by Insiders (%)	4.84%
Owned by Institutions (%)	n/a
Float	19.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.19
PB Ratio	6.89
P/TBV Ratio	6.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-10.44
EV / Sales	9.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-29.63

Financial Position

The company has a current ratio of 2.73

Current Ratio	2.73
Quick Ratio	2.64
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -74.82% and return on invested capital (ROIC) is -47.32%.

Return on Equity (ROE)	-74.82%
Return on Assets (ROA)	-31.36%
Return on Invested Capital (ROIC)	-47.32%
Return on Capital Employed (ROCE)	-54.85%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	219,678
Profits Per Employee	-193,177
Employee Count	5
Asset Turnover	0.56
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.27% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+8.27%
50-Day Moving Average	0.56
200-Day Moving Average	0.60
Relative Strength Index (RSI)	50.30
Average Volume (20 Days)	2

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:8WK had revenue of EUR 1.10 million and -965,887 in losses. Loss per share was -0.06.

Revenue	1.10M
Gross Profit	1.10M
Operating Income	-977,437
Pretax Income	-965,887
Net Income	-965,887
EBITDA	-959,788
EBIT	-977,437
Loss Per Share	-0.06

Balance Sheet

The company has 2.17 million in cash and n/a in debt, with a net cash position of 2.17 million.

Cash & Cash Equivalents	2.17M
Total Debt	n/a
Net Cash	2.17M
Net Cash Per Share	n/a
Equity (Book Value)	1.78M
Book Value Per Share	0.10
Working Capital	1.49M

Cash Flow

In the last 12 months, operating cash flow was -301,048 and capital expenditures -39,364, giving a free cash flow of -340,412.

Operating Cash Flow	-301,048
Capital Expenditures	-39,364
Free Cash Flow	-340,412
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of -88.99% and -87.94%.

Gross Margin	100.00%
Operating Margin	-88.99%
Pretax Margin	-87.94%
Profit Margin	-87.94%
EBITDA Margin	-87.38%
EBIT Margin	-88.99%
FCF Margin	n/a

Dividends & Yields

FRA:8WK does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.39%
Shareholder Yield	-17.39%
Earnings Yield	-7.86%
FCF Yield	-2.77%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:8WK has an Altman Z-Score of 3.19 and a Piotroski F-Score of 2.

Altman Z-Score	3.19
Piotroski F-Score	2